The stereoselective distribution of halofantrine enantiomers within human, dog, and rat plasma lipoproteins

Pharmaceutical Research

Volumn 17, Issue 4, 2000, Pages 427-431

  Brocks, Dion R ^a   Ramaswamy, Manisha ^b   MacInnes, Aaron I ^b   Wasan, Kishor M ^b  

^a WESTERN UNIVERSITY OF HEALTH SCIENCES   (United States)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Antimalarial; Enantioselectivity; Lipoprotein distribution

Indexed keywords

HALOFANTRINE; HIGH DENSITY LIPOPROTEIN; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL;

ANTIMALARIAL ACTIVITY; ARTICLE; DRUG DISTRIBUTION; DRUG PROTEIN BINDING; ENANTIOMER; HUMAN; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; PROTEIN LOCALIZATION; SPECIES DIFFERENCE; STEREOCHEMISTRY;

ANIMALS; ANTIMALARIALS; DOGS; HUMANS; LIPOPROTEINS; PHENANTHRENES; RATS; STEREOISOMERISM;

EID: 0034041495     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1007524919865     Document Type: Article

References (20)

1. 1. H. M. Bryson and K. L. Goa. Halofantrine; a review of its antimalarial activity, pharmacokinetic properties and therapeutic potential. Drugs 43:236-258 (1992).
2. 2. S. Krishna, F. ter Kuile, W. Supanaranond, S. Pukrittayakamee, P. Teja-Isavadharm, D. Kyle, and N. J. White. Pharmacokinetics, efficacy and toxicity of parenteral halofantrine in uncomplicated malaria. Br. J. Clin. Pharmacol. 36:585-591 (1993).
3. 3. A. J. Humberstone, C. J. H. Porter, and W. N. Charman. A physiochemical basis for the effect of food on the absolute bioavailability of halofantrine. J. Pharm. Sci. 85:525-529 (1996).
4. 4. D. R. Brocks and J. W. Toni. Pharmacokinetics of halofantrine in the rat: Stereoselectivity and interspecies comparisons. Biopharm. Drug Dispos. 20:165-169 (1999).
5. 5. J. Karbwang and K. Na Bangchang. Clinical pharmacokinetics of halofantrine. Clin. Pharmacokinet. 27:104-119 (1994).
6. 6. B. Cenni, J. Meyer, R. Brandt, and B. Betschart. The antimalarial drug halofantrine is bound mainly to low and high-density lipoproteins in human serum. Br. J. Clin. Pharmacol. 39:519-526 (1995).
7. 7. M. P. McIntosh, C. J. H. Porter, K. M. Wasan, M. Ramaswamy, and W. N. Charman. Differences in the lipoprotein binding profile of halofantrine in fed and fasted human or beagle plasma are dictated by the respective masses of core apolar lipoprotein lipid. J. Pharm. Sci. 88:378-84 (1999).
8. 8. K. M. Wasan, M. Ramaswamy, M. P. McIntosh, C. J. H. Porter, and W. N. Charman. Differences in the lipoprotein distribution of halofantrine are regulated by lipoprotein apolar lipid and protein concentration and lipid transfer protein I activity: In vitro studies in normolipidemic and dyslipidemic human plasma. J. Pharm. Sci. 88:185-190 (1998).
9. 9. A. J. Humberstone, C. J. H. Porter, G. A. Edwards, and W. N. Charman. Association of halofantrine with postprandially derived plasma lipoproteins decreases its clearance relative to administration in the fasted state. J. Pharm. Sci. 87:936-942 (1998).
10. 10. F. Gimenez, C. Gillotin, L. K. Basco, O. Bouchaud, A. F. Aubry, I. W. Wainer, J. Le Bras, and R. Farinotti. Plasma concentrations of the enantiomers of halofantrine and its main metabolite in malaria patients. Eur. J. Clin. Pharmacol. 46:561-562 (1994).
11. 11. J. M. Karle. X-Ray crystal structure of the antimalarial agent (-)-halofantrine hydrochloride supports stereospecificity for cardiotoxicity. Antimicrob. Agents Chemother. 41:791-794 (1997).
12. 12. K. M. Wasan, S. M. Cassidy, M. Ramaswamy, A. Kennedy, S. P. Ng, F. W. Strobel, and T. Y. Lee. A comparison of stepgradient and sequential density ultracentrifugation and the use of lipoprotein deficient plasma controls in determining the plasma lipoprotein distribution of lipid-associated nystatin and cyclosporine. Pharm. Res. 16:165-169 (1999).
13. 13. D. R. Brocks, M. J. Dennis, and W. H. Schaefer. A liquid Chromatographic assay for the stereospecific quantitative analysis of halofantrine in human plasma. J. Pharm. Biomed. Anal. 13: 911-918 (1995).
14. 14. J. W. Toni and D. R. Brocks. Stereospecific high performance liquid Chromatographic (HPLC) analysis of halofantrine enantiomers in rat plasma. Pharm. Res. 14 (suppl.):568 (1997).
15. 15. L. K. Basco, C. Gillotin, F. Gimenez, R. Farinotti, and J. Le Bras. In vitro activity of the enantiomers of mefloquine, halofantrine and enpiroline against Plasmodium falciparum. Br. J. Clin. Pharmacol 33:517-520 (1992).
16. 16. J. M. Karle, R. Olmeda, L. Gerena, and W. K. Milhous. Plasmodium falciparum: Role of absolute stereochemistry in the antimalarial activity of synthetic amino alcohol antimalarial drugs. Exp. Parasitol 76:345-351 (1993).
17. 17. E. Monlun, P. Le Metayer, S. Szwandt, D. Neau, M. Longy Boursier, J. Horton, and M. Le Bras. Cardiac complications of halofantrine: a prospective study of 20 patients. Trans. R. Soc. Trop. Med. Hyg. 89:430-433 (1995).
18. 18. D. R. Brocks and F. Jamali. Stereochemical aspects of pharmacotherapy. Pharmacotherapy. 15:551-564 (1995).
19. 19. B. Davies and T. Morris. Physiological parameters in laboratory animals and humans. Pharm. Res. 10:1093-1095 (1993).
20. 50 of halofantrine against Plasmodium falciparum. J. Pharm. Sci. 87:256-258 (1998).